Taiho vs. Aurobindo: LONSURF® Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Taiho Pharmaceutical Co., Ltd. et al. v. Eugia Pharma Specialities Ltd. et al. |
| Case Number | 1:19-cv-02309 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Dec 2019 – Apr 2024 4 years 3 months |
| Outcome | Dismissed With Prejudice |
| Patents at Issue | |
| Accused Products | Generic Trifluridine/Tipiracil Tablets (15mg & 20mg) |
Case Overview
The Parties
⚖️ Plaintiff
Japan-based oncology-focused pharmaceutical company and subsidiary of Otsuka Holdings. Taiho Oncology, Inc. markets LONSURF® in North America.
🛡️ Defendant
Vertically integrated generic pharmaceutical group headquartered in India with a significant U.S. commercial presence, specializing in ANDA filings.
Patents at Issue
This Hatch-Waxman litigation centered on two U.S. patents protecting **LONSURF®** (trifluridine and tipiracil) for metastatic colorectal and gastric cancers. These patents cover the active pharmaceutical ingredients and formulations.
- • USRE046284E — Reissued patent protecting composition and/or method-of-use.
- • US10138223B2 — Utility patent covering formulation or method-of-use aspects.
Developing a generic drug?
Check if your pharmaceutical formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was **dismissed with prejudice** by joint stipulation of all parties on April 3, 2024. This outcome reflects a negotiated private resolution, common in Hatch-Waxman pharmaceutical patent disputes. Critically, no damages award was entered, and no injunctive relief was issued by the court.
Key Legal Issues
As a Hatch-Waxman infringement action, the core legal questions would have involved whether Eugia/Aurobindo’s ANDA product infringed the asserted claims of USRE046284E and US10138223B2, and whether those claims were valid. The presence of a reissued patent (USRE046284E) introduced unique litigation dynamics, as defendants often challenge whether claims improperly broadened during reissue are barred by prosecution history estoppel or the recapture rule. These validity complexities likely contributed to the parties seeking a settlement rather than a judicial determination, with the District of Delaware retaining jurisdiction to enforce the confidential settlement terms.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in oncology drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- Analyze related patents in this oncology drug space
- Identify key companies active in generic trifluridine/tipiracil
- Understand patent expiration and market entry timelines
🔍 Check My Drug Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical formulation or product.
- Input your drug description or API details
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for regulatory filing
Reissued Patent Risks
Unique challenges for validity and infringement
Hatch-Waxman Process
Complex regulatory & legal framework
Oncology FTO
Critical for market entry planning
✅ Key Takeaways
Dismissal with prejudice under FRCP 41(a)(1)(A)(ii) signals a private settlement; retained court jurisdiction suggests enforceable resolution terms exist.
Search related case law →Reissued patents in pharmaceutical portfolios introduce recapture-rule and estoppel defenses that should be anticipated and addressed during claim drafting.
Explore precedents →Delaware remains the preferred Hatch-Waxman forum; local counsel selection reflects established jurisdictional strategy.
View District of Delaware case trends →Frequently Asked Questions
The case involved U.S. Patent USRE046284E (a reissued patent) and U.S. Patent No. US10138223B2, both relating to trifluridine and tipiracil tablet formulations marketed as LONSURF®.
The parties stipulated to dismissal under FRCP 41(a)(1)(A)(ii), consistent with a negotiated private resolution. Each party bore its own costs, and specific settlement terms were not publicly disclosed.
It reinforces that Hatch-Waxman disputes — even those involving complex oncology portfolios and reissued patents — frequently resolve through negotiated agreement, underscoring the importance of pre-litigation portfolio strength and early settlement analysis.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — U.S. Federal Court Records (Case 1:19-cv-02309)
- USPTO Patent Center — Patent USRE046284E
- USPTO Patent Center — Patent US10138223B2
- Cornell Legal Information Institute — 35 U.S.C. § 289
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.